- About Us
- Nano-Social Network
- Nano Consulting
- My Account
January 19th, 2005
Melbourne pharmaceutical developer Starpharma Holdings is on the verge of signing a strategic deal with Dow Chemical Company that would shore up its intellectual property position and give it access to an estimated 200 patents in the competitive field of nanotechnology.
The deal, which could be finalised by the end of next week, is expected to involve the transfer of Dow's extensive intellectual property portfolio into Starpharma's subsidiary Dendritic Nanotechnologies (DNT). In return, Dow will receive a 31 per cent equity stake in DNT.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Fast track control accelerates switching of quantum bits December 16th, 2016
GLOBALFOUNDRIES Demonstrates Industry-Leading 56Gbps Long-Reach SerDes on Advanced 14nm FinFET Process Technology: Proven ASIC IP solution will enable significant performance and power efficiency improvements for next-generation high-speed applications December 13th, 2016
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016